# Maternal Therapy With TAF Versus TDF to Prevent Vertical Transmission of Hepatitis B

> **NCT04211805** · — · UNKNOWN · sponsor: **New Discovery LLC** · enrollment: 450 (estimated)

## Conditions studied

- Hepatitis B, Chronic
- Pregnancy Related

## Interventions

- **DRUG:** Tenofovir Alafenamide 25 MG for arm (A)
- **DRUG:** Tenofovir Disoproxil Fumarate 300mg for arm (B)

## Key facts

- **NCT ID:** NCT04211805
- **Lead sponsor:** New Discovery LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-27
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2020-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04211805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04211805, "Maternal Therapy With TAF Versus TDF to Prevent Vertical Transmission of Hepatitis B". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04211805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*